Product restructuring to sweep pharmaceutical firms

Influenced by the government’s plan to slash the price of about half the drugs on the market by an average of 14 percent, a growing number of pharmaceutical firms are scrambled to go through product restructuring starting next April.

The move, designed to reduce national health insurance expenditures, left pharmaceutical companies renewing to clear unprofitable or cost-high medicines with sm...